Cargando...
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...
Guardado en:
| Publicado en: | N Engl J Med |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/ https://ncbi.nlm.nih.gov/pubmed/30730782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|